Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — H1 2025 Earnings Presentation
23 slides from Imricor Medical Systems's earnings presentation, August 2025
Slide 1: 1H 2025 Investor Presentation
rsonal use only 1H 2025 Investor Presentation August 2025 Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer The material contained in this document is a presentation of general background developments and their potential effect upon Imricor. There can be no assurance that future information on Imricor Medical Systems, Inc. (Imricor) and its activities current as of the date developments will be
Slide 3: Contents
Contents Imricor’s vision rsonal use only • • Key highlights • 1H 25 financial results • Looking ahead to 2H 25 and beyond • Q&A Investor Presentation, September 2021 1H2025 1H 2025| | 3
Slide 4: Vision
Vision rsonal use only Imricor's vision is to bring iCMR into every cardiac centre in the world" Investor Presentation, September 2021 Equity Raising 1H 2025| Presentation | 4
Slide 5: Becoming a global med-tech company
Becoming a global med-tech company Current iCMR lab countries Pipeline iCMR lab countries rsonal use only Germany France Sweden Italy Lithuania Denmark Netherlands Switzerland Greece Norway Poland Latvia Croatia Hungary Saudi Arabia Netherlands United States* Qatar Germany *Clinical site Switzerland
Slide 6: Key Highlights
Key Highlights Regulatory Steve rsonal use only • Successful submission of 2nd Premarket Approval (PMA) module to US FDA Wedan • • CE mark approval for 2nd generation Vision-MR ablation catheter CE mark approval for 2nd generation Advantage-MR System • CE mark approval for NorthStar 3D mapping and g
Slide 7: Financial Performance
rsonal use only Financial Performance
Slide 8: Profit and loss
Profit and loss US$’000 HY25 HY24 Service & Other Revenue Revenue 197 408 $41 Equipment rsonal use only Revenue Costs and non-R&D expenses (5,330) (4,454) $21 R&D expenses (5,618) (3,645) HY24 Revenue Other income (expenses), net 649 148 US$’000 EBITDA (10,102) (7,543) Depreciation & Amortization (3
Slide 9: Balance Sheet
Balance Sheet US$’000 Jun-25 Dec-24 Cash and cash equivalents 50,344 15,708 Accounts receivable 255 345 Commentary rsonal use only Inventory 1,221 1,502 • Cash balance increased following completion of a $44.1 Other current assets 573 794 million (A$70 million) capital raise in March 2025 Total curr
Slide 10: Cashflow
Cashflow US$’000 HY25 HY24 Commentary rsonal use only Net loss (13,142) (6,858) • Other non-cash adjustments were up vs. pcp primarily due Other non-cash adjustments 4,113 (685) to increases in the change in fair value charges partially offset by foreign exchange gains. Change in other assets and li
Slide 11: Looking Ahead to 2H 2025 and beyond
Looking Ahead to 2H 2025 rsonal use only and beyond
Slide 12: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers rsonal use only DRIVERS OF GLOBAL CATHETER Electrophysiology Devices Market Size US$bn ABLATION MARKET 40 35 15% CAGR Increased incidence of cardiac dis
Slide 13: Pipeline benefiting from investment in sales
Pipeline benefiting from investment in sales European active pipeline is rebuilding rsonal use only Imricor’s products are currently 30 approved in 31 countries, with 8 countries containing customer sites +93% 25 Estimated over 1,000,000 ablation procedures across the US, EU and 20 Aus in 2023, with
Slide 14: Imricor Regulatory Status – Unlocking the worlds largest market
Imricor Regulatory Status – Unlocking the worlds largest market Imricor Product Suite Approved Status Comment rsonal use only • NorthStar • Advantage-MR EP Recorder/Stimulator • Vision-MR Diagnostic Catheter 2.0 • Full technology platform to • Vision-MR Diagnostic Cable perform real-time iCMR guided
Slide 15: NorthStar – accelerating towards approval and commercialisation
NorthStar – accelerating towards approval and commercialisation rsonal use only Key piece of the infrastructure, intended to be the central hub of every iCMR lab NorthStar Application potential well beyond cardiac ablation Strong in-bound interest from hospitals Solves problem for pediatric hospital
Slide 16: Several key value drivers during 2025/26
Several key value drivers during 2025/26 rsonal use only FDA Approval for US commercial release of platform technology • 510(k) submissions / approvals • VISABL-AFL clinical trial • PMA submissions / approvals VISABL-VT clinical trial • expansion of trial into high volume sites with strong KOL’s Nor
Slide 17: Questions
imric@r ? Questions luo asn jeuosia
Slide 18: Appendix
rsonal use only Appendix
Slide 19: A strong intellectual property portfolio
A strong intellectual property portfolio Imricor’s patents protect technology that allows Imricor to rsonal use only manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. 19 issued U
Slide 20: Imricor Leadership: Management
Imricor Leadership: Management rsonal use only STEVE WEDAN JONATHON GUT GREGG STENZEL NICK CORKILL JENNIFER WEISZ President and Chief Executive Vice President of Finance and Chief Chief Operating Officer Vice President Vice President of Regulatory and Quality Officer, and Board Chair Financial Offic
Slide 21: Imricor Leadership: Board of Directors
Imricor Leadership: Board of Directors rsonal use only STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL Jeffrey Leighton President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Officer, and Board Chair Independent Director Designed
Slide 22: Key Terms
Key Terms Vision-MR Ablation • Medical device developed by Imricor, designed for use within an MRI Catheter • World first, no competitors, all others only compatible with X-ray rsonal use only • Irregular heartbeat, affects approximately 2% of US population • Expected to double to 4% of US populatio
Slide 23: Contact Information
Contact Information Investors & Australian Media: rsonal use only Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.corkill
Imricor Medical Systems — H1 2025 Earnings Presentation on 6ix